Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sino Biopharm Signs $307 Million Deal with Inventiva for NASH Therapy

publication date: Sep 22, 2022

Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Lanifibranor, Inventiva’s lead candidate, is an oral small molecule that induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes. CTTQ will make a $12 million upfront payment and be responsible for up to $295 million in milestone payments, plus royalties. The company will either join the ongoing NATiV3 Phase III clinical trial of lanifibranor in NASH or run an independent study. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China